Clinical trials
Gastrointestinal Stromal Tumors clinical trials
Below are recruiting gastrointestinal stromal tumors clinical trials, each written for real people, not researchers. We’re tracking 51 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07585266RecruitingPhase 3
New drug velzatinib versus imatinib for untreated GIST
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Omaha, NebraskaAges 18 years+ - NCT07406633RecruitingPhase 2
KQB198 plus imatinib for advanced GIST
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT06748690Recruiting
Comparing biopsy methods for stomach tumors
This trial compares two ways to take a tissue sample from stomach tumors before surgery to see which works better. The results may help doctors choose the best method for patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03594422RecruitingPhase 1
Testing an oral drug for GIST or other solid tumors
This Phase 1 trial tests HQP1351, a new oral cancer drug, in people with advanced GIST or other solid tumors that have not responded to prior treatment. It’s mainly designed to check safety and how the drug works in the body, which may lead to better options for tumors that have progressed.
Guangzhou, GuangdongAges 12 years+ - NCT04557969Recruiting
Surgery and tumor testing in gastrointestinal stromal tumors (GIST)
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
Bethesda, MarylandAges 6 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT04933669RecruitingPhase 2
Pre-surgery imatinib for high-risk stomach or gut GIST
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
Hangzhou, ZhejiangAges 18–80 - NCT07697248Recruiting
GIST patient registry study
This study is creating a registry to track people with GIST over time. Participating helps researchers learn more about the disease and improve future care.
Wayne, New JerseyAges Any age - NCT05009927RecruitingPhase 2
Check whether continuing imatinib works after long GIST control
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
BesançonAges 18 years+ - NCT05152472RecruitingPhase 2
Imatinib plus atezolizumab versus imatinib alone for advanced GIST
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Lyon, RhôneAges 18 years+ - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Birmingham, AlabamaAges 18 years+ - NCT05385549RecruitingPhase 2
5-Year imatinib after GIST surgery for high-risk patients
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
Seoul, SeoulAges 20 years+ - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT05500391RecruitingPhase 2
Testing whether remote nurse monitoring works like in-person checks
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
AmiensAges 18 years+ - NCT05905887RecruitingPhase 2
Rivoceranib and paclitaxel for advanced gastrointestinal stromal tumor
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
Seoul, SeoulAges 20 years+ - NCT05938309Recruiting
Safety study of laparoscopic surgery for large stomach GISTs
This study looks at how safe laparoscopic surgery is for stomach GISTs that are 5 cm or larger. If you’re eligible and choose to participate, your team will plan and perform surgery and track safety outcomes.
Fuzhou, FujianAges 18–75 - NCT06523582Recruiting
Genetic study of neuroendocrine tumors in Mexican patients
This study aims to find genetic causes of neuroendocrine tumors in Mexican patients. By understanding your DNA, researchers hope to improve diagnosis and treatment for people with these rare conditions.
Mexico City, Mexico CityAges 18 years+ - NCT06630234RecruitingPhase 1/Phase 2
Testing a new drug for advanced GIST with specific gene changes
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
Scottsdate, ArizonaAges 18 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
Birmingham, AlabamaAges 18 years+ - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT07078136Recruiting
AI study for upper GI tumor diagnosis
This study uses artificial intelligence to help diagnose tumors in the upper stomach or esophagus. It looks at images from endoscopy and ultrasound to improve how doctors identify these growths.
Wuhan, HubeiAges 18 years+ - NCT07171203RecruitingPhase 1
Imatinib and fampridine before surgery for KIT-mutant GIST
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
La Jolla, CaliforniaAges 18 years+ - NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
Phoenix, ArizonaAges 18 years+
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastrointestinal stromal tumors?
- Yes. Clin2 currently lists 51 recruiting gastrointestinal stromal tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastrointestinal stromal tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastrointestinal stromal tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.